Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

Neurooncol Adv · 2021 · PMC8350152 · PMID 34377989

Europe PMC DOI

hedged sentence

0.0209

closest p · 0.4× alpha

0.0209

boldest claim

The sentences

a significant trendP = .0209actually significant

Overall, when comparing 4 distinct groups: (1) high ADC L & BV, (2) low ADC L & BV, (3) high ADC L & VB+BV, and (4) low ADC L & VB+BV there was a significant trend in survival outcomes ( Figure 3F ; Log-rank test for trends, P = .0209), likely dominated by diffusion phenotypes rather than treatment strategy.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.